Replies to post #133775 on Biotech Values

[DewDiligence]

…one caller who asked about if MNTA didn't get the cost-profit share option on the first two FoBs due to BAX already having done work on these FoBs. I kind of got the impression that Wheeler was talking around that a bit so maybe that is the reason MNTA didn't get the cost-profit share option on those first two FoBs.

I highly doubt that BAX has done any prior work on the first two FoB’s in the partnership. The first two FoB’s are treated differently than #3-#6 because (IMO) that’s how the negotiation of the various moving parts in this complex deal shook out.